Lyka Labs (BOM:500259) Cash-to-Debt : 0.16 (As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lyka Labs's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.16.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Lyka Labs couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Lyka Labs's Cash-to-Debt or its related term are showing as below:

BOM:500259' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.16
Current: 0.16

During the past 13 years, Lyka Labs's highest Cash to Debt Ratio was 0.16. The lowest was 0.00. And the median was 0.04.

BOM:500259's Cash-to-Debt is ranked worse than
92.67% of 1527 companies
in the Biotechnology industry
Industry Median: 6.23 vs BOM:500259: 0.16

Lyka Labs Cash-to-Debt Historical Data

The historical data trend for Lyka Labs's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lyka Labs Cash-to-Debt Chart

Lyka Labs Annual Data

Trend

Jun14

Jun15

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

0.01

0.02

0.07

0.16

Lyka Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.07	N/A	0.11	N/A	0.16

Competitive Comparison of Lyka Labs's Cash-to-Debt

For the Biotechnology subindustry, Lyka Labs's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyka Labs's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Cash-to-Debt falls into.

Lyka Labs Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lyka Labs's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	93.777	/	(144.85	+	441.651)
	=	0.16

Lyka Labs's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	93.777	/	(144.85	+	441.651)
	=	0.16

Lyka Labs (BOM:500259) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lyka Labs Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyka Labs (BOM:500259) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

LYKALABS:India

Address

30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036

Website

http://www.lykalabs.com

Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines